Pregnancy and fetal outcomes according to drug exposure subgroups
| Group A: thiopurines | Group B: no thiopurines | Group C: no treatment | |||||||
| Treatment group/subgroup | Alone N=57 | + 5-ASA N=10 | + steroids N=16 | + anti-TNFα N=9 | 5-ASA N=67 | Steroids N=23 | Anti-TNFα N=11 | Methotrexate N=2 | None N=45 |
| Live births (twins included)* | 40 (70.0%) | 9 (90.0%) | 8 (50.0%) | 4 (44.0%) | 48 (71.0%) | 19 (82.0%) | 4 (36.0%) | 0 (0.0%) | 27 (60.0%) |
| Prematurity* | 10 (25.0%) | 2 (22.2%) | 2 (25.0%) | 0 (0.0%) | 6 (12.5%) | 6 (31.5%) | 3 (75.0%) | 0 (0.0%) | 4 (14.8%) |
| Birth weight† | 3078±710 (1900–4300) | 3305±550 (2410–4070) | 3024±546 (2160–3180) | 3266±370 (2900–3640) | 3184±593 (1250–4020) | 2725±762 (1250–3640) | 2312±639 (1720–3130) | 0 | 3289±465 (2300–4070) |
| Low birth weight <2500 g* | 7 (17.5%) | 1 (11.1%) | 1 (12.5%) | 0 (0.0%) | 4 (8.0%) | 6 (31.6%) | 2 (50.0%) | 0 (0.0%) | 2 (7.4%) |
| No. with hypotrophy/hypertrophy | 3/2 | 1/1 | 0/0 | 0/0 | 4/2 | 4/0 | 0/0 | 0/0 | 1/1 |
| No. of congenital abnormalities (*) | 1 (2.5%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 4 (8.3%) | 1 (5.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |